Investment Rating - The report assigns a "Buy" rating to WuXi XDC (02268.HK) for the first time, with a target price of HKD 80, compared to the current price of HKD 58.35 [2][11]. Core Insights - WuXi XDC is positioned to enter a commercialization phase, leveraging its end-to-end integrated CRDMO services and industry-leading technology platform to solidify its leading position in the bioconjugate drug CRDMO sector [1][15]. - The bioconjugate drug industry is experiencing rapid growth, with ADC drugs expected to reach USD 66.2 billion by 2030, and WuXi XDC projected to capture over 24% of the global ADC outsourcing market by 2025 [1][9]. Summary by Relevant Sections Company Overview - WuXi XDC is a joint venture between WuXi Biologics and Hengrui Medicine, focusing on ADC and broader bioconjugate drug markets, providing comprehensive CRDMO services [15][17]. Financial Projections - Revenue projections for WuXi XDC are as follows: - 2024: HKD 4,052 million - 2025: HKD 5,922 million (growth of 46.1%) - 2026: HKD 8,011 million (growth of 35.3%) - 2027: HKD 10,461 million (growth of 30.6%) - Net profit projections are: - 2024: HKD 1,070 million - 2025: HKD 1,481 million (growth of 38.5%) - 2026: HKD 1,989 million (growth of 34.3%) - 2027: HKD 2,600 million (growth of 30.7%) [2][11]. Industry Trends - The bioconjugate drug industry is rapidly expanding, with ADC drugs being the primary focus. The report highlights the emergence of several blockbuster ADC drugs, with six expected to exceed USD 1 billion in sales by 2025 [9][32]. - The outsourcing rate for ADC drugs is projected to remain high at approximately 60%, benefiting companies like WuXi XDC [9][29]. Technological Strengths - WuXi XDC boasts strong technical capabilities with proprietary technologies such as WuXiDARx™, X-LinC conjugation technology, and various payload conjugation platforms, enhancing its competitive edge [7][10]. Capital Expenditure and Growth Strategy - The company plans to invest HKD 1.7 billion in capital expenditures by 2026 to support its global dual-factory production strategy, enhancing its capacity for conjugated raw materials and formulations [7][10]. Market Position - WuXi XDC is expected to have a significant market share in the global ADC outsourcing market, projected to reach over 24% by 2025, reflecting its strong growth trajectory and market demand [1][9].

Core Insights - The company reported a total operating revenue of 2.498 billion yuan for the year 2025, representing a year-on-year growth of 28.23% [1] - The sales revenue of the company's core product, Toripalimab injection (brand name: Tuoyi), in the domestic market saw a significant increase of approximately 37.72% year-on-year [1] - The net profit attributable to the parent company's owners was -874 million yuan, an improvement from -1.281 billion yuan in the same period last year [1]

Core Viewpoint - The company Iwubio (300357.SZ) has received approval for a supplementary application for clinical trials of its drug "Dog Dander Skin Prick Solution" from the National Medical Products Administration, indicating progress in its product development for diagnosing type I hypersensitivity diseases related to dog dander [1] Group 1 - The clinical trial supplementary application for the drug has been approved [1] - The drug is intended for use in skin prick tests to assist in diagnosing type I hypersensitivity diseases associated with dog dander [1]

Group 1 - The company reported a total operating revenue of 1.321 billion yuan for the fiscal year 2025, representing a year-on-year increase of 7.35% [1] - The net profit for the same period was 29.6312 million yuan, showing a significant year-on-year decline of 79.19% [1] - The company made a substantial asset impairment provision during the reporting period [1] Group 2 - The company decided to voluntarily withdraw the drug registration application for Pegylated Interferon α-2 Injection (new hepatitis B indication) based on the latest review suggestions from the National Medical Products Administration [1] - As a result of this decision, the company fully provided for the asset impairment related to the remaining development expenses of this project [1]

Core Viewpoint - The stock of Basilea Pharmaceutica (02616) surged over 8% towards the end of trading, with a current increase of 6.73%, reaching HKD 6.66, and a trading volume of HKD 93.123 million, following the approval of a new indication for Sugli monoclonal antibody by the UK MHRA for treating specific adult patients with non-small cell lung cancer (NSCLC) [1] Company Developments - Basilea Pharmaceutica announced that the UK MHRA has approved the new indication for Sugli monoclonal antibody, which is to be used as a monotherapy for adult patients with unresectable stage III NSCLC who have PD-L1 expression ≥1%, no EGFR sensitive mutations, or ALK/ROS1 genomic alterations, and have not shown disease progression after platinum-based chemoradiotherapy [1] - According to a report from Ping An Securities, Basilea Pharmaceutica is leveraging clinical development as a driving force, with its R&D 1.0 phase commercial products contributing reliable cash flow, while the R&D 2.0 phase focuses on innovative project layouts and cutting-edge technologies [1] Financial Projections - The core products of Basilea Pharmaceutica have entered clinical trial stages, and the company is expected to continue advancing candidate projects into clinical trials [1] - Revenue projections for Basilea Pharmaceutica are estimated to reach HKD 195 million, HKD 464 million, and HKD 633 million for the years 2025, 2026, and 2027, respectively, with the initial coverage rating set at "Recommended" [1]

Core Viewpoint - The company Baiotai has completed clinical trials for the subcutaneous formulation of tocilizumab and is actively preparing for the submission of applications both domestically and for overseas authorization [1] Group 1 - The subcutaneous formulation of tocilizumab has completed clinical trials [1] - Baiotai is currently working on preparations for application submissions [1]

Core Viewpoint - The company, CanSino Biologics (6185.HK), reported a significant turnaround in its financial performance, achieving a profit of 27.87 million yuan for the year ending last December, compared to a loss of 379 million yuan in the previous year [1] Financial Performance - The total revenue for the company reached 1.068 billion yuan, marking a year-on-year increase of 26.18% [1] - The company successfully transitioned from a loss to a profit, indicating effective management and operational improvements [1] Strategic Focus - The company continues to implement a development strategy centered on innovation and commercialization [1] - There has been a strong emphasis on cost reduction and efficiency enhancement, with effective control over various expenses [1] - The optimization of production and sales coordination has contributed to an increase in gross margin [1]

Market Performance - The Hong Kong stock market saw a significant afternoon rally, with the Hang Seng Index rising over 1%, the Hang Seng Tech Index increasing nearly 1%, and the National Enterprises Index up by 0.74% [1] Leading Stocks - New World Development Company Limited (00016) led the gains with a rise of 6.02%, marking a year-to-date increase of 52.59% and a total market capitalization of 418.73 billion [2] - WuXi Biologics (02269) increased by 4.81%, with a year-to-date rise of 27.61% and a market cap of 165.99 billion [2] - CSPC Pharmaceutical Group (01093) saw a 3.67% increase, with a year-to-date gain of 17.32% and a market capitalization of 113.96 billion [2] - WuXi AppTec (02359) rose by 3.04%, with a year-to-date increase of 20.36% and a total market value of 354.47 billion [2] - NetEase (099999) increased by 2.74%, but has a year-to-date decline of 16.22%, with a market cap of 569.25 billion [2] - Trip.com Group (09961) rose by 2.60%, with a year-to-date decline of 25.85% and a market capitalization of 268.5 billion [2] - Tencent Holdings (00700) increased by 2.34%, with a year-to-date decline of 12.52% and a market cap of 4.77 trillion [2] - ZTO Express (09992) rose by 2.32%, with a year-to-date increase of 17.07% and a market capitalization of 149.97 billion [2] - Pop Mart International (09992) increased by 2.31%, with a year-to-date rise of 22.75% and a market cap of 309.09 billion [2] - Mengniu Dairy (02319) rose by 2.10%, with a year-to-date increase of 7.65% and a market capitalization of 62.26 billion [2]

Group 1 - The core point of the article is that Kangfang Biotech (09926) has submitted a New Drug Application (NDA) for its IL-4Rα monoclonal antibody (Mandokizumab, AK120) to the National Medical Products Administration (NMPA) for the treatment of moderate to severe atopic dermatitis (AD) [1] - Following the news, Kangfang Biotech's stock rose nearly 5% in early trading, with a current increase of 4.22%, reaching HKD 106.2, and a trading volume of HKD 456 million [1] - Mandokizumab is the fourth non-oncology drug from Kangfang Biotech to enter the listing application stage, following the approvals or submissions of PCSK9 monoclonal antibody Inusimab, IL-12/IL-23 monoclonal antibody Iroquois, and IL-17A monoclonal antibody Gumokizumab, creating a product matrix covering cardiovascular metabolism, skin, and joint fields [1]

Core Viewpoint - Kangfang Biopharma (09926) has submitted a New Drug Application (NDA) for its IL-4Rα monoclonal antibody (Mandokizumab, AK120) to the National Medical Products Administration (NMPA) for the treatment of moderate to severe atopic dermatitis (AD) [1] Group 1 - Kangfang Biopharma's stock rose nearly 5% in early trading, reaching a price of 106.2 HKD with a trading volume of 456 million HKD [1] - The submission of the NDA for Mandokizumab marks the fourth non-oncology drug that the company has entered the application stage for [1] - The company has previously received approvals or submitted applications for other monoclonal antibodies, including PCSK9 monoclonal antibody Inusimab, IL-12/IL-23 monoclonal antibody Iroquois, and IL-17A monoclonal antibody Gumokizumab, creating a diverse product matrix covering cardiovascular metabolism, skin, and joint diseases [1]